Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 13/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 10/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 10/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30282856 | 1.00 | GABRA5 (0.43) | GABRA5GABRG2GABRB3KCNH2RXRA | |
| SCHEMBL30283165 | 0.88 | RXRA (0.33) | GABRA5GABRG2GABRB3KCNH2RXRA | |
| SCHEMBL25045392 | 0.88 | RXRA (0.33) | GABRA5GABRG2GABRB3KCNH2RXRA | |
| SCHEMBL25045285 | 0.87 | RXRA (0.33) | GABRA5GABRG2GABRB3KCNH2RXRA | |
| SCHEMBL2688352 | 0.87 | GABRA5 (0.54) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL30282901 | 0.87 | GABRA5 (0.54) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL25045396 | 0.87 | GABRA5 (0.44) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL25044752 | 0.87 | GABRA5 (0.44) | GABRA5GABRG2GABRB3KCNH2RXRA | |
| SCHEMBL24240237 | 0.87 | GRIN1 (0.35) | GABRA5GABRG2GABRB3KCNH2RXRA | |
| SCHEMBL25043830 | 0.87 | GABRA5 (0.41) | GABRA5GABRG2GABRB3KCNH2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| WO-2024251133-A1 | HETEROCYCLIC COMPOUND AS α5-GABAA RECEPTOR MODULATOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2024-12-12 | — | — | WO | disclosed |
| EP-4385988-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-115703765-A | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| EP-3823967-B1 | DIFLUOROMETHYL-PHENYL TRIAZOLES AS GABA RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2022-08-31 | — | — | EP | disclosed |
| EP-3823967-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES AS GABA RECEPTOR MODULATORS | Boehringer Ingelheim International GmbH (DE) | 2021-05-26 | — | — | EP | disclosed |
| US-20210147393-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210147393-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-10941137-B2 | Difluoromethyl-phenyl triazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
| US-10941137-B2 | Difluoromethyl-phenyl triazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
| CN-112424197-A | Difluoromethyl-phenyl triazoles as GABA receptor modulators | 勃林格殷格翰国际公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020016443-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES AS GABA RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016443-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES AS GABA RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941137-B2 | Difluoromethyl-phenyl triazoles | GABRA5, GABRB1, GABRA1 | GABRA5 1/4885GABRG2 15/4885GABRB3 5/4885 |
| US-20210147393-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES | GABRA5, GABRB1, GABRA1 | GABRA5 1/4885GABRG2 15/4885GABRB3 5/4885 |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GABRA5, SLC6A11, GABRA1 | GABRA5 1/4885GABRG2 26/4885GABRB3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.